The US Food and Drug Administration (FDA) has granted Fast Track designation to Cereno Scientific’s lead programme, CS1, for the treatment of pulmonary arterial hypertension (PAH). “The Fast Track designation for CS1 underscores the FDA’s recognition of its potential to address the significant unmet need in PAH,” said Rahul Agrawal, CMO & Head of R&D […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!